Oxford Biomedica (LON:OXB) Stock Price Down 10.2% – Should You Sell?

Posted by Trevor Kearing on Feb 24th, 2026

Oxford Biomedica plc (LON:OXB – Get Free Report) traded down 10.2% during trading on Tuesday . The stock traded as low as GBX 689 and last traded at GBX 694.93. 1,073,933 shares changed hands during trading, an increase of 62% from the average session volume of 661,098 shares. The stock had previously closed at GBX 774.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft raised their target price on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a report on Friday, January 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 606.40.

Read Our Latest Research Report on Oxford Biomedica

Oxford Biomedica Stock Performance

The firm has a market cap of £842.20 million, a PE ratio of -19.24 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. The business has a 50 day simple moving average of GBX 754.57 and a two-hundred day simple moving average of GBX 648.79.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.